Health and Justice Buprenorphine Long-Acting (LA) Injection Implementation Review
NHS England Health and Justice (H&J) have commissioned the Medicines Optimisation team at NHS South Central West (NHS SCW) to provide support and subject matter expertise (SME) in relation to reviewing the implementation of Buprenorphine Long Acting (LA) Injection into the 116 H&J sites nationally.
The aims of this programme are to:
provide a comprehensive review of sites that have already implemented the service and those that are yet to.
identify areas of successful service implementation and barriers or challenges to service delivery.
deliver a webinar to share best practice and case study examples in response to information obtained from the review.
collate supportive resources in the form of a Good Practice Pack to support service implementation.
The work complements the programme of work already delivered by Office for Health Improvement and Disparities (OHID) with community substance misuse service providers; so we have resources and information that encourage a consistent approach across community and H&J settings. It is important to note that the programme is not about mandating access to this formulation but provides colleagues in H&J with information to support its introduction.
As part of this programme, we are asking all 116 sites to complete this online survey, please note there should only be one response per site. The findings of the survey will enable us to achieve the aims of the programme and to inform the content of the webinar.
If you have any case studies that you would like to share, please indicate so in the relevant question within the survey and we will be in touch with you.
We thank you in advance for your support and co-operation in completing this survey in a timely manner. Please submit the completed survey and attach all relevant documentation by 25th November 2022.
NHS England Health and Justice (H&J) have commissioned the Medicines Optimisation team at NHS South Central West (NHS SCW) to provide support and subject matter expertise (SME) in relation to reviewing the implementation of Buprenorphine Long Acting (LA) Injection into the 116 H&J sites nationally.
The aims of this programme are to:
provide a comprehensive review of sites that have already implemented the service and those that are yet to.
identify areas of successful service implementation and barriers or challenges to service delivery.
deliver a webinar to share best practice and case study examples in response to information obtained from the review.
collate supportive resources in the form of a Good Practice Pack to support service implementation.
The work complements the programme of work already delivered by Office for Health Improvement and Disparities (OHID) with community substance misuse service providers; so we have resources and information that encourage a consistent approach across community and H&J settings. It is important to note that the programme is not about mandating access to this formulation but provides colleagues in H&J with information to support its introduction.
As part of this programme, we are asking all 116 sites to complete this online survey, please note there should only be one response per site. The findings of the survey will enable us to achieve the aims of the programme and to inform the content of the webinar.
If you have any case studies that you would like to share, please indicate so in the relevant question within the survey and we will be in touch with you.
We thank you in advance for your support and co-operation in completing this survey in a timely manner. Please submit the completed survey and attach all relevant documentation by 25th November 2022.
